Immunosuppressive factors: Role in cancer development and progression

International Journal of Biological Markers

Volumn 13, Issue 2, 1998, Pages 51-69

  Botti, C ^a   Seregni, E ^a   Ferrari, L ^a   Martinetti, A ^a   Bombardieri, E ^a  

^a NATIONAL CANCER INSTITUTE   (Italy)

Author keywords

Adhesion molecules; Cancer; Colony stimulating factors (CSFs); Gangliosides (GMs); Immunosuppressive acidic protein (IAP); Immunosuppressive factors; Interleukin 10 (IL 10); Mucins; Prostaglandin E2 (PGE2); Protein p15E; Suppressive E receptor (SER); Transforming growth factor beta (TGF )

Indexed keywords

ACUTE PHASE PROTEIN; ALPHA FETOPROTEIN; CELL ADHESION MOLECULE; COLONY STIMULATING FACTOR; GANGLIOSIDE; IMMUNOSUPPRESSIVE ACID PROTEIN; IMMUNOSUPPRESSIVE AGENT; INTERLEUKIN 10; MUCIN; PROSTAGLANDIN E2; TRANSFORMING GROWTH FACTOR BETA;

CANCER; HUMAN; IMMUNE DEFICIENCY; REVIEW; TUMOR IMMUNITY;

SANGUISORBA;

EID: 0031770411     PISSN: 03936155     EISSN: None     Source Type: Journal    
DOI: 10.1177/172460089801300201     Document Type: Review

References (221)

1. Sulitzeanu D. Immunosuppressive factors in human cancer. Adv Cancer Res 1993; 60: 247-67.
2. O'Sullivan GC, Corbett AR, Shanan F, Collins JK. Regional immune-suppression in esophageal squamous cancer: evidence from functional studies with matched lymph nodes. J Immunol 1996; 157: 4717-20.
3. Nicolini A, Ferrari P, Spinelli R, Carpi A, Sagripanti A, Ambrogi F. Cell-mediated immunity in breast cancer patients. Biomed Pharmacother 1996; 50: 337-43.
4. Monson JRT, Ramsden CW, Giles GR, Brennan TG, Guillou PJ. Lymphokine activated (LAK) cells in patients with gastrointestinal cancer. Gut 1987; 28: 1420-5.
5. Shu S, Chou T, Rosenberg SA. In vitro sensitization and expansion with viable tumor cells and inteleukin 2 in the generation of specific therapeutic effector cells. J Immunol 1986; 136: 3891-8.
6. Ting CC, Hargrove ME, Stephany D. Generation of activated killer cells in tumor bearing hosts. Int J Cancer 1987; 39: 232-9.
7. MacCubin DL, Mace KF, Ehrke MJ, Mihich E. Modification of host antitumor defense mechanisms in mice by progressively growing tumor. Cancer Res 1989; 49: 4216-24.
8. Favrot MC, Combaret S, Negrier I, et al. Functional and immunophentotypic modifications induced by interleukin-2 did not predict response to therapy in patients with renal cell carcinoma. J Biol Resp Modif 1990; 9: 167-77.
9. Whiteside TL, Heo DS, Takagi S, Johnson JT, Iwatsuki S, Herberman RB. Cytolytic antitumor effector cells in long-term cultures of human tumor-infiltrating lymphocytes in recombinant interleukin 2. Cancer Immunol Immunother 1988; 26: 1-10.
10. Mullen CA, Urban JL, van Waes C, Rowley DA, Schreiber H. Multiple cancers. Tumor burden permits the outgrowth of other cancers. J Exp Med 1985; 162: 1665-82.
11. Torre-Amione G, Beauchamp RD, Koeppen H et al. A highly immunogenic tumor transfected with a murine transforming growth factor type beta 1 cDNA escapes immune surveillance. Proc Natl Acad Sci USA 1990; 87: 1486-90.
12. Hoagland JG, Scoggin S, Gaivazzi R, Campbell D, Kanellopoulos K, Jessup JM. Tumor-derived suppressor factors (TDSFs) in normal and neoplastic colon and rectum. J Surg Res 1986; 40: 467-74.
13. Miescher S, Whiteside TL, Carrel S, von Fliedner V. Functional properties of tumor-infiltrating and blood lymphocytes in patients with solid tumors: effects of tumor cells and their supernatants on proliferative responses of lymphocytes. J Immunol 1986; 136: 1899-1907.
14. Santoli D, Tweardy DJ, Ferrero D, Kreidr BL, Rovera G. A suppressor lymphokine produced by tumor T leukemia cell lines. Partial characterization and spectrum of activity against normal and malignant hemopoietic cells. J Exp Med 1986; 163: 18-40.
15. Shirakawa F, Tanaka Y, Oda S, et al. Immunosuppressive factors from adult T-cell leukemia cells. Cancer Res 1986; 46: 4458-62.
16. Tanaka Y, Shirakawa F, Oda S, et al. Effect of immunosuppressive factors produced by adult T cell leukemia cells on B cell responses. Jpn J Cancer Res 1987; 78: 1390-9.
17. Ebert EC, Roberts AI, O'Connel SM, Robertson FM, Nagase H. Characterization of an immunosuppressive factor derived from colon cancer cells. J Immunol 1987; 138: 2161-68.
18. Paietta E, Stockert RJ, Calvelli T et al. HL-T, a new cell line derived from HL-60 promyelocytic leukemia cell cultures expressing terminal transferase and secreting suppressor activity. Blood 1987; 70: 1151-60.
19. Montaldo PG, Lanciotti M, Castagnola E, et al. A human acute leukemia-derived T-cell line produces two inhibitor factors which suppress lymphocyte proliferation: characterization and purification of the molecules. Lymphokine Res 1988; 7: 413-27.
20. Ponzoni M, Montaldo PG, Lanciotti M, Castagnola E, Cirillo C, Cornaglia-Ferraris P. Purification to homogeneity and biochemical characterization of two suppressor factors from human malignant T cells. Biochem Biophys Res Commun 1988; 150: 702-10.
21. Abolhassani M, Muraki J, Chiao JW. Purification of a suppressor lymphokine (SL) from a human T-cell line. Immunol Invest 1989; 18: 741-751.
22. Burton JD, Weitz CH, Kay NE. Malignant chronic lymphocytic leukemia B cells elaborate soluble factors that down-regulate T cell and NK function. Am J Hematol 1989; 30: 61-7.
23. Guillou PJ, Sedman PC, Ramsden CW. Inhibition of lymphokine-activated killer cell generation by cultured tumor cell line in vitro. Cancer Immunol Immunother 1989; 28: 43-53.
24. Guillou PJ, Ramsden CW, Somers SS, Sedman PC. Suppression of the generation of lymphokine activated killer (LAK) cells by serum-free supernatants of in vitro maintained tumour cell lines. Br J Cancer 1989; 59: 515-21.
25. Muraki J, Fischer J, Addonizio JC, Nagamatsu GR, Chiao JW. Immunosuppressive factor derived from renal cancer cells. Urology 1989; 34: 205-9.
26. Matsuzaki N, Okada T, Kameda T, Negoro T, Saji F, Tanizawa O. Trophoblast-derived immunoregulatory factor: demonstration of the biological function and the physicochemical characterization of the factor derived from choriocarcinoma cell lines. Am J Reprod Immunol 1989; 19: 121-7.
27. Matsuzaki N, Okada T, Kameda T, Negoro T, Saji F, Tanizawa O. Analysis of site of action of a choriocarcinoma immunoregulatory factor on IL-2-mediated T cell responses. J Reprod Immunol 1989; 15: 181-94.
28. Telerman A, Merluzzi VJ, Cavelli TA, Kunicka JE, Platsoucas CD. Hybridoma-derived human suppressor factors: differential effects on mouse lymphocytes. Hybridoma 1989; 8: 25-36.
29. Olt G, Berchuck A, Soisson AP, Boyer CM, Bast RC. Fibronectin is an immunosuppressive substance associated with epithelial ovarian cancer. Cancer 1992; 70: 2137-42.
30. Morvillo V, Bover L, Mordoh J. Identification and characterization of a 14-kDa immunosuppressive protein derived from IIB-MEL-J, a human melanoma cell line. Cell Mol Biol 1996; 42: 779-95.
31. Kanayama H, Hamazoe R, Osaki Y, Shimizu N, Maeta M, Koga S. Immunosuppressive factors from the spleen in gastric cancer patients. Cancer 1985; 56: 1963-6.
32. Sugiyama Y, Sakata K, Saji S, Takao H, Hamuro J. Effects of serum immunosuppressive factors on antitumor cytotoxicity of interleukin 2-induced lymphocytes. J Surg Oncol 1987; 35: 223-29.
33. Stromberg PC, McMurray DN, Brown CA. Inhibition of in vitro mitogen-induced lymphoproliferative responses by sera from F344 rats with large granular lymphocyte leukemia. J Clin Lab Immunol 1988; 25: 89-95.
34. Itoh K, Pellis NR, Balch CM. Monocyte-dependent, serum-born suppressor of induction of lymphokine-activated killer cells in lymphocytes from melanoma patients. Cancer Immunol Immunother 1989; 29: 57-62.
35. Zhou QH, Yang ZH, Zhang HB, Yang JJ, Xiao YK. Pre- and postoperative sequential study on the immunosuppressive activity of serum and cell-free skin bleb fluid of patients with lung cancer and esophageal cancer. J Surg Oncol 1989; 41: 121-7.
36. Bugis SP, Lotzova E, Savage HE, et al. Inhibition of lymphokine-activated killer cell generation by blocking factors in sera of patients with head and neck cancer. Cancer Immunol Immunother 1990; 31: 176-81.
37. Medoff JR, Clack VD, Roche JK. Characterization of an immunosuppressive factor from malignant ascites that resembles a factor induced in vitro by carcinoembryonic antigen. J Immunol 1986; 137: 2057-64.
38. Fujii M, Takahashi N, Hayashi H, Matsunaga K, Yoshikumi C. Purification and characterization of immunosuppressive (IS) substance obtained from ascitic fluids of patients with gastrointestinal cancer. Clin Biochem 1987; 20: 183-9.
39. Cornelius JG, Normann SJ. Isolation of a low molecular weight inhibitor of lymphocyte proliferation from tumorous ascites. J Immunol 1988; 141: 2175-80.
40. Cohen R, Contino M, Hensen DK et al. Heterogeneity of soluble suppressor factors in rat malignant ascites. Oncology 1988; 45: 230-5.
41. Koseki H, Shiiba K, Suzuki Y, Asanuma T, Matsumo S. Enhanced expression of lipocortin-1 as a new immunosuppressive protein in cancer patients and its influence on reduced in vitro peripheral blood lymphocyte response to mitogens. Surg Today 1997; 27: 30-9.
42. Rifkin DB, Kojima S, Abe M, Harpel JG. TGF-beta: structure, function and formation. Thromb Haemost 1993; 70: 177-9.
43. Kingsley DM. The TGF-beta superfamily: new members, new receptors, and new genetic tests of function in different organisms. Genes Dev 1994; 8: 133-46.
44. Roberts AB, Anzano MA, Lamb LC, Smith JM, Sporn MB. New class of transforming growth factors potentiated by epidermal growth factor: isolation from non-neoplastic tissues. Proc Natl Acad Sci USA 1981; 78: 5339-43.
45. Anzano MA, Roberts AB, Smith JM, Sporn MB, De Larco JE. Sarcoma growth factor from conditioned medium of virally transformed cells is composed of both type alpha and type beta transforming growth factors. Proc Natl Acad Sci USA 1983; 80: 6264-8.
46. Koli K, Heski-Oja J. Transforming Growth Factor-β system and its regulation by members of the steroid-thyroid hormone superfamily. Adv Cancer Res 1996; 70: 63-94.
47. Barnard JA, Lyons RM, Moses HL. The cell biology of transforming growth factor beta. Biochim Biophys Acta 1990; 1032: 79-87.
48. Norgaard P, Hougaard S, Poulsen HS, Spang-Thomsen M. Transforming growth factor beta and cancer. Cancer Treat Rev 1995; 21: 367-403.
49. Blanckaert VD, Schelling ME, Elstadt CA, Meadows GG. Differential grwoth factor production, secretion and response by high and low metastatic variants of B16BL6 melanoma. Cancer Res 1993; 53: 4075-81.
50. Susaki A, Naganuma H, Satoh E, et al. Secretion of transforming growth factor-beta 1 and beta 2 by malignant glioma cells. Neurol Med Chir 1995; 35: 423-30.
51. Takanami I, Imamura T, Hashizume T, Kikuchi K, Yamamoto Y, Kodaira S. Transforming growth factor beta 1 as a prognostic factor in pulmonary adenocarcinoma. J Clin Pathol 1994; 47: 1098-100.
52. Friedman E, Gold LI, Klimstra D, Zeng ZS, Winawer S, Cohen A. High levels of transforming growth factor beta 1 correlate with disease progression in human colon cancer. Cancer Epidemiol Biomarkers Prev 1995; 4: 549-54.
53. Kehrl JH, Wakefield LM, Roberts AB et al. Production of transforming growth factor beta by human T lymphocytes and its possible role in the regulation of T cell growth. J Exp Med 1986; 163: 1037-50.
54. Kehrl JH, Thevenin C, Rieckmann P, Fauci AS. Transforming growth factor-beta suppresses human B lymphocyte Ig production by inhibiting synthesis and switch from the membrane form to the secreted form of Ig mRNA. J Immunol 1991; 146: 4016-23.
55. Wahl SM, Hunt DA, Wong HL, et al. Transforming growth factor-beta is a potent immunosuppressive agent that inhibits IL-1 dependent lymphocyte proliferation. J Immunol 1988; 140: 3026-32.
56. Cross D, Cambier JC. Transforming growth factor beta 1 has differential effects on B cell proliferation and activation of antigen expression. J Immunol 1990; 144: 432-9.
57. Ranges GE, Figari IS, Espevik T, Palladino MA. Inhibition of cytotoxic T cell development by transforming growth factor beta and reversal by recombinant tumor necrosis factor alpha. J Exp Med 1987; 166: 991-8.
58. Grimm EA, Crump WL, Durett A, Hester JP, Lagoo-Deenadalavan S, Oween-Schaub LB. TGF beta inhibits the in vitro induction of lymphokine-activated killing activity. Cancer Immunol Immunother 1988; 27: 53-8.
59. Kasid A, Bell GI, Director EP. Effects of transforming growth factor-beta on human lymphokine activated killer cell precursor. Autocrine inhibition of cellular proliferation and differentiation to immune killer cells. J Immunol 1988; 141: 690-8.
60. Mule JJ, Schwartz SL, Roberts AB, Sporn MB, Rosenberg SA. Transforming growth factor-beta inhibits the in vitro generation of lymphokine-activated killer cells and cytotoxic T cells. Cancer Immunol Immunother 1988; 26: 95-100.
61. Fontana A, Frei K, Bodmer S et al. Transforming growth factor-beta inhibits the generation of cytotoxic T cells in virus-infected mice. J Immunol 1989; 143: 3230-4.
62. Jin B, Scott JL, Vadas MA, Burns GF. TGF beta down-regulates TLiSA 1 expression and inhibits the differentiation of precursor lymphocytes into CTL and LAK cells. Immunology 1989; 66: 570-6.
63. Tada T, Ohzeki S, Utsumi K, et al. Transforming growth factor-beta-induced inhibition of T cell function. Susceptibility difference in T cells of various phenotypes and functions and its relevance to immunosuppression in the tumor-bearing state. J Immunol 1991; 146: 1077-82.
64. Rook AH, Kehrl JH, Wakefield LM et al. Effects of transforming growth factor beta on the functions of natural killer cells: depressed cytolytic activity and blunting of interferon responsiveness. J Immunol 1986; 136: 3916-20.
65. Wallick SC, Figari IS, Morris RE, Levinson AD, Palladin MA. Immunoregulatory role of transforming growth factor beta (TGF-beta) in development of killer cells: comparison of active and latent TGF-beta 1. J Exp Med 1990; 172: 1777-84.
66. Tsunawaki S, Sporn MB, Ding A, Nathan C. The activation of macrophages by transforming growth factor beta. Nature 1988; 334: 260-2.
67. Fischer JR, Schindel M, Stein N, et al. Selective suppression of cytokine secretion in patients with small-cell lung cancer. Ann Oncol 1995; 6: 921-6.
68. Czarnieki CW, Chiu HH, Wong GH, McCabe S, Palladino MA. Transforming growth factor-beta 1 modulates the expression of class II histocompatibility antigens on human cells. J Immunol 1988; 140: 4217-23.
69. Zuber P, Kuppner MC, De Tribolet N. Transforming growth factor-beta 2 down-regulates HLA-DR antigen expression on human malignant glioma cells. Eur J Immunol 1988; 18: 1623-26.
70. Brooks WH, Netsky MG, Normansell DE, Horwitz DA. Depressed cell-mediated immunity in patients with primary intracranial tumors. Characterization of a humoral immunosuppressive factor. J Exp Med 1972; 136: 1631-47.
71. Fontana A, Hengartner H, De Tribolet N, Weber E. Glioblastoma cells release interleukin 1 and other factors inhibiting interleukin 2-mediated effects. J Immunol 1984; 132: 1837-44.
72. Roszman TL, Brooks WH, Elliot LH. Inhibition of lymphocyte responsiveness by a glial tumor cell derived suppressive factor. J Neurosurg 1987; 67: 874-9.
73. Wrann M, Bodmer S, de Martin R et al. T cell suppressor factor from human glioblastoma cells is 12.5-kD protein closely related to transforming growth factor-beta. EMBO J 1987; 6: 1633-6.
74. Bodmer S, Strommer K, Frei K, et al. Immunosuppression and transforming growth factor-beta in glioblastoma. Preferential production of transforming growth factor-beta-2. J Immunol 1989; 143: 3222-9.
75. Wahl SM, Hunt DA, Bansal G, McCartney-Francis N, Ellinsworth L, Allen JB. Bacterial cell wall induced immunosuppression. Role of transforming growth factor beta. J Exp Med 1988; 168: 1403-17.
76. Hirte H, Clark DA. Generation of lymphokine-actvated killer cells in human ovarian carcinoma ascitic fluid: identification of transforming growth factor-beta as a suppressive factor. Cancer Immunol Immunother 1991; 32: 296-302.
77. Wilson AP, Fox H, Scott IV, Lee H, Dent M, Golding PR. A comparison of the growth-promoting properties of ascitic fluids, cyst fluids and peritoneal fluids from patients with ovarian tumours. Br J Cancer 1991; 63: 102-8.
78. Ivanovic V, Melman A, Davis-Joseph B, Valcic M, Geliebter J. Elevated plasma levels of TGF-β1 in patients with invasive prostate cancer. Nature Med 1995; 1:282-4.
79. Eder IE, Stenzl A, Cronauer MV, Bartsch G, Klocker H. Transferring growth factor B1 and B2 and basic fibroblast growth factor in serum and urine from patients with bladder cancer. Proc Am Assoc Cancer Res 1995; 36: 245.
80. Shirai Y, Kawata S, Ito N, et al. Elevated levels of plasma transforming growth factor β in patients with hepatocellular carcinoma. Jpn J Cancer Res 1992; 83: 676-9.
81. Berg DJ, Lynch RG. Immune dysfunction in mice with plasmacytomas. I. Evidence that transforming growth factor beta contributes to the altered expression of activation receptors on host B lymphocytes. J Immunol 1991; 146: 2865-72.
82. Mathes LE, Olsen RG, Hebebrand LC, Hoover EA, Schaller JP. Abrogation of lymphocyte blastogenes by a feline leukaemia virus protein. Nature 1978; 274: 687-9.
83. Mathes LE, Olsen RG, Hebebrand LC, et al. Immunosuppressive properties of a virion polypeptide, a 15-dalton protein, from feline leukemia virus. Cancer Res 1979; 39: 950-5.
84. Jacquemin PC, Strijckmans P, Thiry L. Study of the expression of a glycoprotein of retroviral origin in the plasma of patients with hematologic disorders and in the plasma of normal individuals. Blood 1984; 64: 832-41.
85. Cianciolo GJ, Copelan TD, Oroszlan S, Snyderman R. Inhibition of lymphocyte proliferation by a synthetic peptide homologous to retroviral envelope proteins. Science 1985; 230: 453-5.
86. Kleinerman ES, Lachman LB, Knowles RD, Snyderman R, Cianciolo GJ. A synthetic peptide homologous to the envelope proteins of retroviruses inhibits monocyte-mediated killing by inactivating interleukin 1. J Immunol 1987; 139: 2329-37.
87. Harris DT, Cianciolo GJ, Snyderman R, Argov S, Koren HS. Inhibition of human natural killer cell activity by a synthetic peptide homologous to a conserved region in the retroviral protein p15E. J Immunol 1987; 138: 889-94.
88. Harrell RA, Cianciolo GJ, Copeland TD, Oroszlan S, Snyderman R. Suppression of the respiratory burst of human monocytes by a synthetic peptide homologous to envelope proteins of human and animal retroviruses. J Immunol 1986; 136: 3517-20.
89. Ogasawara M, Cianciolo GJ, Snyderman R, Mitari M, Good RA, Day NK. Human IFN-gamma production is inhibited by a synthetic peptide homologous to retroviral envelope protein. J Immunol 1988; 141: 614-9.
90. Nelson M, Nelson DS. Inhibition of interleukin-2 production by tumor cell products and by CKS 17, a synthetic retroviral envelope peptide. Cancer Immunol Immunother 1990; 30: 331-41.
91. Nelson M, Nelson DS, Cianciolo GJ, Snyderman R. Effects of CKS-17, a synthetic retroviral envelope peptide, on cell-mediated immunity in vivo: immunosuppression, immunogenicity, and relation to immunosuppressive tumor products. Cancer Immunol Immunother 1989; 30: 113-8.
92. Nelson M, Nelson DS, Spradbrow PB et al. Successful tumor immunotherapy: possible role of antibodies to anti-inflammatory factors produced by neoplasms. Clin Exp Immunol 1985; 61: 109-17.
93. Moore KW, O'Garra A, Malefyt RW, Vieira P, Mosmann TR. Interleukin-10. Ann Rev Immunol 1993; 11: 165-90.
94. Taga K, Tosato G. IL-10 inhibits human T cell proliferation and IL-2 production. J Immunol 1992; 148: 1143-8.
95. Gastl GA, Abrams JS, Nanus DM, et al. Interleukin-10 production by human carcinoma cell lines and its relationship to interleukin-6 expression. Int J Cancer 1993; 55: 96-101.
96. Kim J, Modlin RL, Moy RL et al. IL-10 production in cutaneous basal and squamous carcinomas: a mechanism for evading the local T cell immune response. J Immunol 1995; 155: 2240-7.
97. Bost KL, Bieligk SC, Jaffe BM. Lymphokine mRNA expression by transplantable murine B lymphocytic malignancies. Tumor-derived IL-10 as a possible mechanism for modulating the anti-tumor response. J Immunol 1995; 154: 718-29.
98. Alleva DG, Burger CJ, Elgert KD. Tumor induced regulation of suppressor macrophage nitric oxide and TNF-alpha production. Role of tumor-derived IL-10, TGF-β and prostaglandin E2. J Immunol 1994; 153: 1674-86.
99. Cortes JE, Talpaz M, Cabanillas F, Seymour JF, Kuzrock R. Serum levels of interleukin-10 in patients with diffuse large cell lymphoma: lack of correlation with prognosis. Blood 1995; 85: 2516-20.
100. Kucharzik T, Lugering N, Winde G, Domschke W, Stoll R. Colon carcinoma cell lines stimulate monocytes and lamina propria mononuclear cells to produce IL-10. Clin Exp Immunol 1997; 110: 296-302.
101. Honn KV, Bockman RS, Marnett LJ. Prostaglandins and cancer: a review of tumor initiation through tumor metastasis. Prostaglandins 1981; 21: 833-50.
102. Schrey MP, Patel KV. Prostaglandin E2 production and metabolism in human breast cancer cells and breast fibroblasts: regulation by inflammatory mediators. Br J Cancer 1995; 72: 1412-9.
103. Bennet A, Del-Tacca M, Stamford IF, Zebro T. Prostaglandins from tumours of human large bowel. Br J Cancer 1977; 35: 881-4.
104. Hubbard WC, Alley MC, McLemore TL, Boyd MR. Profiles of prostaglandin biosynthesis in sixteen established cell lines derived from human lung, colon, prostate and ovarian tumors. Cancer Res 1988; 48: 4770-5.
105. Narisawa T, Kusaka H, Yamazaki Y, et al. Relationship between blood plasma prostaglandin E2 and liver and lung metastases in colorectal cancer. Dis Colon Rectum 1990; 33: 840-5.
106. Neoptolemos JP, Husband D, Imray C, Rowley S, Lawson N. Arachidonic acid and docosahexaenoic acid are increased in human colorectal cancer. Gut 1991; 32: 278-81.
107. Thun MJ, Namboodiri MM, Heath CW. Aspirin use and reduced risk of fatal colon cancer. New Engl J Med 1991; 325: 1593-6.
108. Marnett LJ. Aspirin and related nonsteroidal anti-inflammatory drugs as chemopreventive agents against colon cancer. Prev Med 1995; 24: 103-6.
109. Rao CV, Rivenson A, Simi B, et al. Chemoprevention of colon carcinogenesis by sulindac, a nonsteroidal anti-inflammatory agent. Cancer Res 1995; 55: 1464-72.
110. Mnich SJ, Veenhuizen AW, Monahan JB, et al. Characterization of a monoclonal antibody that neutralizes the activity of prostaglandin E2. J Immunol 1995; 155: 4437-44.
111. Rassnick S, Zhou D, Rabin BS. Central administration of prostaglandin E2 suppresses in vitro cellular immune responses. Am J Physiol 1995; 269: R92-7.
112. Baxevanis CN, Reclos GJ, Gritzapis AD, Dedouis GV, Missitzis I, Papamichail M. Elevated prostaglandin E2 production by monocytes is responsible for the depressed levels of natural killer and lymphokine-activated killer cell function in patients with breast cancer. Cancer 1993; 72: 491-501.
113. Goodwin JS, Ceuppens JL. Regulation of the immune response by prostaglandins. J Clin Immunol 1984; 3: 295-315.
114. Stephan RN, Conrad PJ, Saizawa M, Dean RE, Chaudry IH. Prostaglandin E2 depresses antigen presenting cell function of peritoneal macrophages. J Surg Res 1988; 44: 733-9.
115. Rappaport RS, Dodge GR. Prostaglandin E inhibits the production of human interleukin II. J Exp Med 1982; 155: 943-8.
116. Arvind P, Papavassiliou ED, Tsioulias GJ, et al. Prostaglandin E2 down-regulates the expression of HLA-DR antigen in human colon adenocarcinoma cell lines. Biochemistry 1995; 34: 5604-9.
117. Andrews FJ, Halliday GM, Muller HK. A role of prostaglandins in the suppression of cutaneous cellular immunity and tumour development in benzo(a)pyrene but not dimethylbenz(a)anthracene treated mice. Clin Exp Immunol 1991; 85: 9-13.
118. Seregni E, Boni C, Ballabio G, Bombardieri E. Molecular characteristics and genetic control of mucins. Tumour Marker Update 1995; 7: 1-3.
119. Seregni E, Botti C, Massaron S, et al. Structure, function and gene expression of epithelial mucins. Tumori 1997; 83: 625-32.
120. Kjeldsen T, Clausen H, Hirohashi S, Ogawa T, Iijima H, Hakomori S. Preparation and characterization of monoclonal antibodies directed to the tumor-associated O-linked sialosyl 2-6 N acetylgalactosaminyl (sialosyl-Tn) epitope. Cancer Res 1988; 48: 2214-20.
121. Itzkowitz SH, Yuan M, Montgomery CK, et al. Expression of Tn, sialosyl-Tn, and T antigens in human colon cancer. Cancer Res 1989; 49: 197-204.
122. Itzkowitz SH, Bloom EJ, Lau T, Kim YS. Mucin-associated Tn and sialosyl-Tn antigen expression in colorectal polyps. Gut 1992; 33: 518-23.
123. Itzkowitz SH, Kjeldsen T, Friera A, Hakomori S, Yang U, Kim YS. Expression of Tn, sialosyl-Tn and T antigens in human pancreas. Gastroenterology 1991; 100: 1691-1700.
124. Werther JL, Rivera-MacMurray S, Tatematsu M, Ito N, Bruckner H, Itzkowitz SH. Sialosyl-Tn: a novel mucin antigen associated with poor prognosis in gastric cancer patients. Proc Am Assoc Cancer Res 1991; 32: 241-7.
125. Johnston WW, Szpak CA, Lottich SC, Thor A, Schlom J. Use of a monoclonal antibody (B72.3) as an immunocytochemical adjunct to diagnosis of adenocarcinoma in human effusions. Cancer Res 1985; 45: 1894-1900.
126. Itzkowitz SH, Bloom EJ, Kokal WA, Modin G, Hakomori S, Kim YS. Sialosyl-Tn: a novel mucin antigen associated with prognosis in colorectal cancer patients. Cancer 1990; 66: 1960-6.
127. Van Rinsum J, Smets LA, Van Rooy H, Van den Eijnden DH. Specific inhibition of human natural killer cell-mediated cytotoxicity by sialic acid and sialooligosaccharides. Int J Cancer 1986; 38: 915-22.
128. Ogata S, Maimonis PJ, Itzkowitz SH. Mucins bearing the cancer-associated sialosyl-Tn antigen mediate inhibition of natural killer cytotoxicity. Cancer Res 1992; 52: 4741-76.
129. Ligtenberg MJ, Vos HL, Gennissen AM, Hilkens J. Episialin, a carcinoma-associated mucin, is generated by a polymorphic gene encoding splice variants with alternative amino termini. J Biol Chem 1990; 265: 5573-8.
130. Hayes DF, Sckine H, Marcus D, Alper CA, Kufe DW. Genetically determined polymorphism of the circulating human breast cancer-associated DF3 antigen. Blood 1988; 71: 436-40.
131. Sekine H, Ohno T, Kufe DW. Purification and characterization of a high molecular weight glycoprotein detectable in human milk and breast carcinomas. J Immunol 1985; 135: 3610-5.
132. Abe M, Kufe DW. Identification of a family of high molecular weight tumor-associated glycoproteins. J Immunol 1987; 139: 257-61.
133. Kufe D, Inghirami G, Abe M, Hayes D, Justi-Wheeler H, Schlom J. Differential reactivity of a novel monoclonal antibody (DF3) with human malignant versus benign breast tumors. Hybridoma 1984; 3: 223-32.
134. Hayes DF, Silberstein DS, Rodrique SW, Kufe DW. DF3 antigen, a human epithelial cell mucin, inhibits adhesion of eosinophils to antibody-coated targets. J Immunol 1990; 145: 962-70.
135. van de Wiel-van Kemenade E, Ligtenberg MJL, de Boer AJ, et al. Episialin (MUC1) inhibits cytotoxic lymphocyte-target cell interaction. J Immunol 1993; 151: 767-76.
136. Gimmi CD, Morrison BW, Mainprice BA, et al. Breast cancer-associated antigen, DF3/MUC1, induces apoptosis of activated human T cells. Nature Med 1996; 2: 1367-70.
137. Agrawal BA, Krantz MJ, Reddish MA, Longenecker BM. Cancer-associated mucin inhibits human T-cell proliferation, which is reversible by IL-2. Nature Med 1998; 4: 43-9.
138. Oh SK, Very DL, Walker J, Raam S, Ju ST. An analogy between fetal haptoglobin and a potent immunosuppressant in cancer. Cancer Res 1987; 47: 5120-6.
139. Oh Sk, Leung MF, Knee T, Williams JM. Biological properties of suppressive E-receptor factor on lymphokine function. Eur J Immunol 1987; 17: 1403-9.
140. Oh SK, Ross S, Walker J, Zeisel S. Role of a SER immune suppressor in immune surveillance. Immunology 1988; 64: 73-9.
141. Oh SK, Kim SH, Walker JE. Interference with immune response at the level of generating effector cells by tumor-associated haptoglobin. J Natl Cancer Inst 1990; 82: 934-40.
142. Oh SK, Very DL, Ettinger R, Walker J, Gianpaolo C, Bernardo J. Monoclonal antibody to SER immune suppressor detects polymeric forms of haptoglobin. Hybridoma 1989; 8: 449-66.
143. Tamura K, Shibata Y, Matsuda Y, Ishida N. Isolation and characterization of an immunosuppressive acidic protein from ascitic fluids of cancer patients. Cancer Res 1981; 41: 3244-52.
144. Shibata Y, Tamura K, Ishida N. Cultured human monocytes, granulocytes and a monoblastoid cell line (TPH-1) synthesize and secrete immunosuppressive acidic protein (a type of alpha-1-acid glycoprotein). Microbiol Immunol 1984; 28: 99-111.
145. Ishida N, Shibata Y, Tamura K. Serum protein factors against self defense, which are activated in cancer patients: role of macrophage. In: Mizuno D, Cohn ZA, Takeja K, Ishida N, eds. Self defense mechanism. Tokyo: Life Science, 1982; 243-54.
146. Miki T, Kohoda N, Oda H, et al. A study of measurement of serum immunosuppressive acidic protein levels with germinal testicular cancers. Jpn J Urol 1984; 75: 1883-9.
147. Castelli M, Romano P, Atlante G, Pozzi M, Ferrini U. Immunosuppressive acidic protein (IAP) and CA 125 assays in detection of human ovarian cancer: preliminary results. Int J Biol Markers 1987; 2: 187-90.
148. Pummer K, Purstner P, Auner HL, et al. Serum immunosuppressive acid protein predicts lymph node metastases in patients with renal cell carcinoma. Br J Urol 1994; 73: 612-4.
149. Oka M, Mitsunaga H, Hazama S, Yoshino S, Suzuki T. Natural killer activity and serum immunosuppressive acidic protein levels in esophageal gastric cancers. Surg Today 1993; 23: 669-74.
150. Law SKA. Antigen shedding and metastasis of tumour cells. Clin Exp Immunol 1991; 85: 1-2.
151. Chiba I, Jin R, Hamada J, Hosokawa M, Takeichi N, Kobayashi H. Growth-associated shedding of a tumor antigen (CE7) detected by a monoclonal antibody. Cancer Res 1989; 49: 3972-5.
152. Vinuela JE, Rodriguez R, Gil J, Dela Concha EG, Subiza JL. Antigen shedding vs. development of natural suppressor cells as mechanism of tumor escape in mice bearing Erlich tumor. Int J Cancer 1991; 47: 86-91.
153. Takahashi K, Ono K, Hirabayashi Y, Taniguchi M. Escape mechanism of melanoma from immune system by soluble melanoma antigen. J Immunol 1988; 3244-8.
154. Tsujiaki M, Imai K, Hirata H, et al. Detection of circulating intercellular adhesion molecule-1 antigen in malignant diseases. Clin Exp Immunol 1991; 85: 3-8.
155. Harning R, Mainolfi E, Bystryn JC, Henn M, Merluzzi VJ, Rothlein R. Serum levels of circulating intercellular ahesion molecule 1 in human malignant melanoma. Cancer Res 1991; 51: 5001-5.
156. Williams AF, Barclay AN. The immunoglobulin super-family domains for cell surface recognition. Ann Rev Immunol 1988; 6: 381-405.
157. Rothlein R, Dustin ML, Marlin SD, Springer TA. A human intercellular adhesion molecule (ICAM-1) distinct from LFA-1. J Immunol 1986; 137: 1270-4.
158. Marlin SD, Springer TA. Purified intercellular adhesion molecule (ICAM-1) is a ligand for lymphocyte function-associated antigen 1 (LFA-1). Cell 1987; 51: 813-9.
159. Makgoba MW, Sanders ME, Ginther-Luce GE, et al. ICAM-1, a ligand for LFA-1 dependent adhesion of B, T and myeloid cells. Nature 1988; 331: 86-8.
160. Vanky F, Wang P, Patarroyo M, Klein E. Expression of the adhesion molecule ICAM-1 and major histocompatibility complex class I antigens on human tumor cells is required for their interaction with autologous lymphocytes in vitro. Cancer Immunol Immunother 1990; 31: 19-27.
161. Timonem T, Patarroyo M, Gahmberg CG. CD1 la-c/CD18 and GP84 (LB-2) adhesion molecules on human large granular lymphocytes and their participation in natural killing. J Immunol 1988; 141: 1041-6.
162. Makgoba MW, Sanders ME, Ginther-Luce GE, et al. Functional evidence that intercellular adhesion molecule 1 (ICAM-1) is a ligand for LFA-1 dependent adhesion in T cell mediated cytotoxicity. Eur J Immunol 1988; 18: 637-40.
163. Dustine ML, Rothlein R, Bhan AK, Dinarello CA, Springer TA. Induction by IL-1 and interferon-g: tissue distribution, biochemistry, and function of a natural adhesion molecule (ICAM-1). J Immunol 1986; 137: 245-54.
164. Rivoltini L, Cattoretti G, Arienti F, et al. The high lysability by LAK cells for colon-carcinoma cells resistant to doxorubicin is associated with a high expression of ICAM-1, LFA-3; NCA and a less differentiated phenotype. Int J Cancer 1991; 47: 746-54.
165. Natali P, Nicotra MR, Cavaliere R, et al. Differential expression of intercellular adhesion molecule 1 in primary and metastatic melanoma lesions. Cancer Res 1990; 50: 1271-8.
166. Tomita Y, Nishiyama T, Watanabe H, Fujiwara M, Sato S. Expression of intercellular adhesion molecule-1 (ICAM-1) on renal cell cancer: possible significance in host immune responses. Int J Cancer 1990; 46: 1001-6.
167. Koyama S, Ebihara T, Fukao K. Expression of intercellular adhesion molecule 1 (ICAM-1) during the development of invasion and/or metastasis of gastric carcinoma. J Cancer Res Clin Oncol 1992; 118: 609-14.
168. Koyama S. Immunosuppressive effect of shedding intercellular adhesion molecule 1 antigen on cell-mediated cytotoxicity against tumor cells. Jpn J Cancer Res 1994; 85: 131-4.
169. Ritter G, Livingston PO. Ganglioside antigens expressed by human cancer cells. Sem Cancer Biol 1991; 2: 401-9.
170. Portoukalian J, David MJ, Gain P, Richard M. Shedding of GD2 ganglioside in patients with retinoblastoma. Int J Cancer 1993; 53: 948-51.
171. Higashi H, Hirabayashi Y, Hirota M, Matsumoto M, Kato S. Detection of ganglioside GM2 in sera and tumour tissues of hepatoma patients. Jpn J Cancer Res 1987; 78: 1309-13.
172. Ladisch S, Wu SL, Feig S, et al. Shedding of GD2 ganglioside by human neuroblastoma. Int J Cancer 1987; 39: 73-6.
173. Dyatlovitskaya EV, Bergelson LD. Glycosphyngolipids and antitumour immunity. Biochim Biophys Acta 1987; 907: 125-43.
174. Prokazowa NV, Dyatlovitskaya EV, Bergelson LD. Sialylated lactosyl ceramides. Possible inducers of non-specific immunosuppression and atherosclerotic lesions. Eur J Biochem 1988; 172: 1-6.
175. Marcus DM. A review of the immunogenic and immunomodulatory properties of glycosphyngolipids. Mol Immunol 1984; 21: 1083-91.
176. Ikeda T, Nakakuma H, Shionoya H, Kawaguchi T, Yamatsu K, Takatsuki K. Ganglioside induced inhibition of in vivo immune response in mice. Life Sci 1992; 51: 847-51.
177. Ladisch S, Gillard B, Wong C, Ulsh L. Shedding and immunoregulatory activity of YAC-1 lymphoma cell gangliosides. Cancer Res 1983; 43: 3808-13.
178. Hoon DS, Irie RF, Cochran AJ. Gangliosides from human melanoma immunomodulate response of T cells to interleukin-2. Cell Immunol 1988; 115: 410-9.
179. Floutsis G, Ulsh L, Ladisch S. Immunosuppressive activity of human neuroblastoma tumor gangliosides. Int J Cancer 1989; 43: 6-9.
180. Miller HC, Esselman WJ. Modulation of the immune response by antigen reactive lymphocytes after cultivation with gangliosides. J Immunol 1975; 115: 839-43.
181. Ladisch S, Ulsh L, Gillard B, Wong C. Modulation of the immune response by gangliosides. Inhibition of adherent monocyte accessory function in vitro. J Clin Invest 1984; 74: 2074-81.
182. Merrit WD, Bailey M, Pluznik DH. Inhibition of interleukin-2-dependent cytotoxic T-lymphocyte growth by gangliosides. Cell Immunol 1984; 89: 1-10.
183. Grayson G, Ladisch S. Immunosuppression by human gangliosides. II. Carbohydrate structure and inhibition of human NK activity. Cell Immunol 1992; 139: 18-29.
184. Lu P, Sharom FJ. Gangliosides are potent immunosuppressors of IL-2 mediated T-cell proliferation in a low protein environment. Immunology 1995; 86: 356-63.
185. Seregni E, Botti C, Bombardieri E. Biochemical characteristics and clinical applications of alpha fetoprotein isoforms. Anticancer Res 1995; 15: 1491-1500.
186. Cohen BL, Om A, Gronvik KO, Gidlund M, Wigzell H, Murgita RA. Suppression by alpha fetoprotein of murine natural killer cell activity stimulated in vitro and in vivo by interferon and interleukin 2. Scand J Immunol 1986; 23: 211-23.
187. Murgita RA, Goidl EA, Kontianen SS, Wigzell H. Alpha-fetoprotein induces suppressor T cells in vitro. Nature 1977; 267: 257-9.
188. Peck AB, Murgita RA, Wigzell H. Cellular and genetic restrictions in immunoregulatory activity of alpha-fetoprotein. III. Role of the MLC-stimulating cell population in alpha-fetoprotein induced suppression of T cell-mediated cytotoxicity. J Immunol 1982; 128: 1134-40.
189. Murgita RA, Tomasi TB. Suppression of the immune response by alpha-fetoprotein on the primary and secondary antibody response. J Exp Med 1975; 141: 269-86.
190. Auer IO, Kress HG. Suppression of the primary cell-mediated immune response by human alpha 1-fetoprotein in vitro. Cell Immunol 1977; 30: 173-9.
191. Littman BH, Alpert E, Rocklin RE. The effect of purified alpha-fetoprotein on in vitro assays of cell-mediated immunity. Cell Immunol 1977; 30: 35-42.
192. Olinescu A, Laky M, Popescu DE, Dumitrescu A, Ganea D. The effect of alpha-fetoprotein on the immune response. III. Diminution of the phagocytic capacity of macrophage cultures in vitro in the presence of mouse amniotic fluid or alpha-fetoprotein. Arch Roum Pathol Exp Microbiol 1977; 36: 247-53.
193. Yamashita T, Nakane A, Watanabe T, Miyoshi I, Kasai N. Evidence that alpha-fetoprotein suppresses the immunological function in transgenic mice. Biochem Biophys Res Commun 1994; 201: 1154-9.
194. Ralph P, Warren MK, Lee MT, et al. Inducible production of human macrophage growth factor, CSF-1. Blood 1986; 68: 633-9.
195. Evans R, Duffy TM, Blake SS, Lin HS. Regulation of systemic macrophage IL-1 gene transcription: the involvement of tumor-derived macrophage growth factor, CSF-1. J Leukocyte Biol 1989; 46: 428-43.
196. Hardy C, Balducci L. Hemopoietic alterations of cancer. Am J Med Sci 1985; 290: 196-205.
197. Tsuchiya Y, Igarashi M, Suzuki R, Kumagai K. Production of colony-stimulating factor by tumor cells and the factor-mediated induction of suppressor cells. J Immunol 1988; 141: 699-708.
198. Fu Y-X, Watson G, Jimenez JJ, Wang Y, Lopez DM. Expansion of immunoregulatory macrophages by granulocyte-macrophage colony-stimulatory factor derived from a murine mammary tumor. Cancer Res 1990; 50: 227-34.
199. Fu Y-X, Watson GA, Kasahara M, Lopez DM. The role of tumor-derived cytokines on the immune system of mice bearing a mammary adenocarcinoma. I. Induction of regulatory macrophages in normal mice by the in vivo administration of rGM-CSF. J Immunol 1991; 146: 783-9.
200. Samak R, Edelstein R, Israel L. Immunosuppressive effect of acute-phase reactanct proteins in vitro and its relevance to cancer. Cancer Immunol Immunother 1982; 13: 38-43.
201. Baumann H, Wong GG. Hepatocyte-stimulating factor III shares structural and functional identity with leukemia-inhibitory factor. J Immunol 1989; 143: 1163-7.
202. Evans R, Kamdar SJ, Duffy TM. Tumor-derived products induce IL-1a, IL-1β, TNF- a, and IL-6 gene expression in murine macrophages: distinctions between tumor- and bacterial endotoxin-induced gene expression. J Leukocyte Biol 1991; 46: 474-82.
203. Szymkowiak CH, Mons I, Gross WL, Kekow J. Determination of transforming growth factor β2 in human blood samples by ELISA. J Immunol Meth 1995; 184: 263-71.
204. Kong FM, Anscher MS, Murase T, Abbott BD, Iglehart JD, Jirtle RL. Elevated plasma transforming growth factor-β1 levels in breast cancer patients decrease after surgical removal of the tumor. Ann Surg 1995; 222: 155-62.
205. Kopp A, Jonat W, Schmahl M, Knabbe C. Transforming growth factor-β2 (TGF-β2) levels in plasma of patients with metastatic breast cancer treated with tamoxifen. Cancer Res 1995; 55: 4512-5.
206. Wakefield LM, Letterio JJ, Chen T, et al. Transforming growth factor-β1 circulates in normal human plasma and is unchanged in advanced metastatic breast cancer. Clin Cancer Res 1995; 1: 129-36.
207. Assoian RK, Sporn MB. Type β transforming growth factor in human platelets: release during platelet degranulation and action on vascular smooth muscle cells. J Cell Biol 1986; 102: 1217-23.
208. Klapan I, Katic V, Culo F, Cuk V. Prognostic significance of plasma prostaglandin E concentration in patients with head and neck cancer. J Cancer Res Clin Oncol 1992; 118: 308-13.
209. Piantino P. CA19.9. In: Ballesta AM, Torre GC, Bombardieri E, Gion M, Molina R, eds. Updating on tumor markers in tissues and in biological fluids: basic aspects and clinical applications. Torino: Minerva Medica, 1993; 497-505.
210. Landoni F, Arioso M, D'Amico P, et al. The clinical significance of the tumor marker CA 125. In: Ballesta AM, Torre GC, Bombardieri E, Gion M, Molina R, eds. Updating on tumor markers in tissues and in biological fluids: basic aspects and clinical applications. Torino: Minerva Medica, 1993; 507-23.
211. Hayes DF, Tondini C, Kufe DW. CA 15.3. In: Ballesta AM, Torre GC, Bombardieri E, Gion M, Molina R, eds. Updating on tumor markers in tissues and in biological fluids: basic aspects and clinical applications. Torino: Minerva Medica, 1993; 525-35.
212. Guadagni F, Roselli M, Ferroni P, et al. Clinical value of the TAG 72 tumor marker in the management of carcinoma patients. In: Ballesta AM, Torre GC, Bombardieri E, Gion M, Molina R, eds. Updating on tumor markers in tissues and in biological fluids: basic aspects and clinical applications. Torino: Minerva Medica, 1993; 555-68.
213. Barba D, Saris SC, Holder C, Rosenberg SA, Oldfield EH. Intratumoral LAK cell and interleukin 2 therapy of human gliomas. J Neurosurg 1989; 70: 175-82.
214. Prehn RT. The inhibition of tumor growth by tumor mass. Cancer Res 1991; 51: 2-4.
215. Yuan L, Kuramitsu Y, Li Y, Kobayashi M, Hosokawa M. Restoration of interleukin-2 production in tumor-bearing rats through reducing tumor-derived transforming growth factor β by treatment with bleomycin. Cancer Immunol Immunother 1995; 41: 355-62.
216. Arteaga CL, Carty-Dugger T, Moses H, Hurd S, Pietenpol J. Transforming growth factor beta 1 can induce estrogen-independent tumorigenicity of human breast cancer cells in athymic mice. Cell Growth Differ 1993; 4: 193-201.
217. Wojtowicz-Praga S, Verma UN, Wakefield L, Esteban JM, Hartmann D, Mazumder A. Modulation of B 16 melanoma growth and metastasis by anti-transforming growth factor beta antibody and interleukin-2. J Immunother 1996; 19: 169-75.
218. Fakrai H, Dorigo O, Shawler DL, et al. Eradication of established intracranial rat gliomas by transforming growth factor beta antisense gene therapy. Proc Natl Acad Sci USA 1996; 93: 2909-14.
219. Chao TY, Ting CS, Yeh MY, Chang JY, Wang CC, Chu TM. Effects of indomethacin on lymphokine-activated killer cell activities in cancer patients. Tumor Biol 1995; 16: 230-42.
220. Boolbol SK, Dannenberg AJ, Chadburn A, et al. Cyclooxygenase-2 overexpression and tumor formation are blocked by sulindac in a murine model of familial adenomatous polyposis. Cancer Res 1996; 56: 2556-60.
221. Nugent KP, Spigelman AD, Phillips RKS. Tissue prostaglandin levels in familial adenomatous polypesis patients treated with sulindac. Dis Colon Rectum 1996; 39: 659-62.